Included in the advice is a strong recommendation for the use of Pfizer’s Paxlovid (nirmatrelvir/ritonavir) in mild or moderate COVID-19 patients who are at high risk of hospitalisation.
Pregnant or breastfeeding women with non-severe COVID-19 should consult with their doctor to determine whether they should take the orally administered drug, WHO said, which cited its ‘likely benefits’ and a lack of adverse events which have been reported.
WHO also reviewed the evidence on two other medicines, GSK/Vir Biotechnology’s Xevudy (sotrovimab) and Regeneron/Roche’s REGEN-COV (casirivimab/imdevimab), and maintains strong recommendations against their use for treating COVID-19…
